Our History Header.jpg
Our History page thumbnail.jpg

Our History

BBI Solutions history timeline

BBI was founded in 1986, when John Chandler at Cardiff University developed and manufactured our now world-renowned gold nanoparticles for the first time and supplied them to the electron microscopy industry.

Since then, the company has grown its portfolio of products to include gold reagents, antibodies, antigens, enzymes, serum and plasma, cell culture reagents as well as offering antibody development services,
lateral flow assay development and manufacture, and of course, our Novarum™ smartphone diagnostic platform.

See how we have grown

1986

The BBI Group was established in 1986 with only 10 staff…

And had a turnover of less than £1 Million.

2000

BBI achieved an MBO.

2004

BBI achieved an IPO.

2006

Growth continues through the product and service, acquisitions and new entities.

2008

The BBI Group was sold to Alere for £85m. Alere are a global POC leader.

2013

We rebranded to bring our complete offering together as BBI Solutions.

2015

The BBI Group became an independent company following an the acquisition by Exponent Private Equity.

2016

BBI Solutions acquired Novarum DX Ltd.

2018

Invested £14m in the new BBI Group Global Headquarters.

2020

April 2020, BBI Group joins the UK Rapid Test Consortium to rapidly develop and rollout the Coronavirus tests.

June 2020, BBI Group acquires DIARECT AG, establishing BBI as the leading provider of antigens in the autoimmune and tick-borne IVD markets

BBI Solutions Brands

diarect.png

The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.

mbs.png

Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.

Newsletter

Signup for our newsletter to receive the latest BBI Solutions updates and special offers in your inbox